Discovery of a High Affinity, Orally Bioavailable Macrocyclic FXIa Inhibitor with Antithrombotic Activity in Preclinical Species.Yang, W., Wang, Y., Lai, A., Clark, C.G., Corte, J.R., Fang, T., Gilligan, P.J., Jeon, Y., Pabbisetty, K.B., Rampulla, R.A., Mathur, A., Kaspady, M., Neithnadka, P.R., Arumugam, A., Raju, S., Rossi, K.A., Myers Jr., J.E., Sheriff, S., Lou, Z., Zheng, J.J., Chacko, S.A., Bozarth, J.M., Wu, Y., Crain, E.J., Wong, P.C., Seiffert, D.A., Luettgen, J.M., Lam, P.Y.S., Wexler, R.R., Ewing, W.R.
(2020) J Med Chem 63: 7226-7242
- PubMed: 32456431
- DOI: https://doi.org/10.1021/acs.jmedchem.0c00464
- Primary Citation of Related Structures:
- PubMed Abstract:
Oral factor XIa (FXIa) inhibitors may provide a promising new antithrombotic therapy with an improved benefit to bleeding risk profile over existing antithrombotic agents. Herein, we report application of a previously disclosed cyclic carbamate P1 linker which provided improved oral bioavailability in the imidazole-based 13-membered macrocycle to the 12-membered macrocycle. This resulted in identification of compound 4 with desired FXIa inhibitory potency and good oral bioavailability but high in vivo clearance. Further structure-activity relationship (SAR) studies of heterocyclic core modifications to replace the imidazole core as well as various linkers to the P1 group led to the discovery of compound 6f , a potent FXIa inhibitor with selectivity against most of the relevant serine proteases. Compound 6f also demonstrated excellent pharmacokinetics (PK) profile (high oral bioavailability and low clearance) in multiple preclinical species. Compound 6f achieved robust antithrombotic efficacy in a rabbit efficacy model at doses which preserved hemostasis.
Research and Development, Bristol Myers Squibb Company, P.O. Box 5400, Princeton, New Jersey 08540, United States.